Celularity Inc. 2019 Q2 10-Q — Filing identity discrepancy
The supplied filing is for GX Acquisition Corp., not Celularity Inc. It covers the quarter ended June 30, 2019 and was signed August 7, 2019. The summary below reflects the filing text provided; confirm the correct issuer filing before relying on it.
Business context and reporting period
GX Acquisition Corp. describes itself as a newly formed blank-check company seeking a merger or other business combination. It had not begun operations and had no operating revenue through June 30, 2019. Its IPO closed May 23, 2019. It had until May 23, 2021 to complete a business combination or liquidate.
Financial results and liquidity
| Metric | Three months ended June 30, 2019 | Six months ended June 30, 2019 |
|---|---|---|
| Operating and formation costs | $115,250 | $115,371 |
| Trust-account interest and unrealized gains | $918,585 | $918,585 |
| Net income | $634,660 | $634,539 |
| Net income attributable to redeemable shares | $664,565 | $664,565 |
| Adjusted loss attributable to other common shares | $(29,905) | $(30,026) |
- At June 30, 2019, assets totaled $289.7 million, including $288.4 million in trust-account marketable securities and $1.17 million of cash outside the trust.
- Total liabilities were $11.0 million, including a $10.8 million deferred underwriting fee payable only if a business combination is completed. No long-term debt was reported.
- Cash used in operating activities for the six months was $194,810. Investing activities used $287.5 million, principally for the trust account; financing activities provided $288.8 million.
- The IPO raised $287.5 million gross; a further $7.0 million came from sponsor private-placement warrants. Reported transaction costs were $16.47 million.
- Margins are not meaningful for this pre-operating shell company. Basic and diluted loss per share attributable to nonredeemable common shares was reported as $(0.00) for both periods.
Changes, outlook, risks, and unusual items
- The IPO and private placement were completed during the quarter, creating the trust assets and substantially changing the balance sheet from December 31, 2018. The filing provides no prior-year comparable-quarter results.
- Management expected to use trust funds, subject to redemptions and deferred underwriting fees, toward a business combination. It said it did not expect to need additional funds for planned expenditures, but warned that cost overruns, significant redemptions, or transaction needs could require financing; no assurance was given that a transaction would be completed.
- Public shareholders may redeem shares in connection with a business combination. If no transaction closes by May 23, 2021, the company must wind up and redeem public shares, subject to the stated terms. Warrants may expire worthless if the company liquidates.
- The sponsor’s trust-protection indemnity has limitations, and the filing says the sponsor’s ability to satisfy it was not verified. Other risks include potential dilution or debt in a transaction and the possibility of insufficient cash outside the trust.
- Related-party and transaction arrangements included a $10,000 monthly administrative-support fee and a $12,500 monthly consulting arrangement. The company reported $20,000 of administrative fees and $15,500 of consulting fees incurred for the three and six months ended June 30.
- Management reported effective disclosure controls and no material change in internal control over financial reporting. It reported no legal proceedings and no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm issuer identity: the provided text identifies GX Acquisition Corp., despite the request naming Celularity Inc.
- Reconcile the filing’s inconsistent IPO-unit count: the financial statements and other sections state 28.75 million units, while one MD&A passage states 27.5 million.
- Check the original filing for the unusual cover-page response indicating the company had not filed all required Exchange Act reports, and assess its significance in context.
- Review trust-account terms, redemption mechanics, deferred underwriting fees, sponsor indemnity capacity, and the May 23, 2021 transaction deadline.